Treatment of Mycosis Fungoides with Hypericin Ointment and Visible Light

Inclusion Criteria:

• Subjects must have a clinical diagnosis of cutaneous T-cell lymphoma (CTCL, mycosisfungoides), Stage 1A, Stage 1B, or Stage 2A.

(Stage 1 is divided into stages 1A and 1B as follows: Stage 1A: Patches, papules, and/or plaques cover less than 10% of the skin surface. Stage 1B: Patches, papules, and/or plaques cover 10% or more of the skin surface. Stage 2A: Patches, papules, and/or plaques cover any amount of skin surface. Lymph nodes are abnormal, but they are not cancerous.)

• Subjects willing to follow the clinical protocol and voluntarily give their writteninformed consent

• Female subjects not pregnant nor nursing and willing to undergo a pregnancy testwithin 21 days prior to treatment initiation and agree to use a medically acceptedmethod of birth control such as oral contraceptives (birth control pill), Barriermethod (condom plus spermicide or diaphragm plus spermicide) or abstaining fromintercourse while on study

Exclusion Criteria:

• History of allergy or hypersensitivity to any of the components of SGX301

• Pregnancy or mothers who are breast-feeding

• Males and females not willing to use effective contraception

• Subjects with history of sun hypersensitivity or photosensitive dermatoses (e.g.,porphyria, systemic lupus erythematosus, Sjogren's, etc.).

• Subjects whose condition is spontaneously improving.

• Subjects receiving topical steroids or other topical treatments (e.g., nitrogenmustard) on lesions for CTCL within 2 weeks of enrollment

• Subjects receiving systemic steroids, psoralen UVA radiation therapy (PUVA), narrowband UVB light therapy (NB-UVB) or carmustine (BCNU) or other systemic therapies forCTCL within 3 weeks of enrollment

• Subjects who have received electron beam irradiation within 3 months of enrollment

• Subjects with a history of significant systemic immunosuppression

• Subjects taking other investigational drugs or drugs of abuse within 30 days ofenrollment

• Subject with any condition that, in the judgment of the PI, is likely to interferewith participation in the study

• Subjects receiving drugs known to cause photosensitization within 2 weeks ofstarting SGX301 therapy unless they have not had evidence of photosensitizationafter receiving a stable dose of the medication for a minimum of 4 weeks.